




5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS



Virtual Meet

22nd - 24th
JULY 2022

ORGANISING
TEAM



Dr. Anil Heroor
Director Surgical Oncology,
Fortis Hospital,
Mumbai



Dr. Tejinder Singh
Sr. Consultant Medical Oncologist,
Apollo Cancer Center,
Apollo Hospital, Mumbai



Dr. Adwaita Gore
Associate Director Medical Oncology,
Nanavati Max Super Speciality Hospital,
Mumbai

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute**
Leaders in Streaming Modules

We bring

accessible innovation
for improved patient care



Introduced for the 1st time in the world


Bryxta **300**
Bevacizumab 300mg/12ml

- Avoid significant reduction in drug wastage & offer price benefit to the patients
- Improve patient compliance
- Reduce the burden of overall cost of therapy

**The only Bevacizumab biosimilar
with a comprehensive range.**





5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 1 | 22nd July 2022 Scientific Program

Industry Symposium

6:00pm – 6:30pm

Supported by Bristol Myers Squibb
Immune checkpoint inhibitors in 1L
Gastric Cancer, GEJC and EAC

Speaker: Dr. Tejinder Singh

6:30pm – 7:00pm

Supported by Intas
Role of S1 in GI management in
Indian Scenario

Speaker: Dr. Prabhat Bhargava

7:00pm – 7:30pm

Supported by AstraZeneca
Newer Avenues in Management of
Advanced BTC

Speaker: Dr. B.K. Smruti

7:30pm – 8:00pm

Supported by Lilly
Recent Advances in the
Management of Second Line
Gastric Cancer

Speaker: Dr. Ashish Singh

8:00pm – 8:30pm

Supported by Roche
Panel Discussion on Treatment
Strategies with Atezolizumab &
Bevacizumab in Unresectable HCC

Moderator: Dr. Bhushan Nemade

Panelists –
Dr. Tejinder Singh
Dr. Preetam Jain
Dr. Ameet Mandot
Dr. Rahul Sheth

8:30pm – 9:00pm

**Supported by Johnson and Johnson
Medtech**
Science of Tissue Management

Speaker: Dr. Vineet Agarwal



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 2 | 23rd July 2022 **Scientific Program**

Session 1 : Esophagus/Stomach Cancers

6:00pm – 6:10pm	<p>Chairpersons - Dr. Shirish Alurkar Dr. Girish Phadke</p> <p>Updates in Surgical Management of Localized EG Cancers</p> <p>Speaker: Dr. M. Satish Kumar</p>
6:10pm – 6:20pm	<p>Management of Metastatic EG Cancer</p> <p>Speaker: Dr. Pritam Kalaskar</p>
6:20pm – 6:40pm	<p>Should all Patients with EG Cancer Receive Immunotherapy?</p> <p>Yes – Dr. M. Vamshi Krishna</p> <p>No – Dr. Peush Bajpai</p> <p>Debate Moderator : Dr. Bharat Bhosale</p>
6:40pm – 7:10pm	<p>Chairpersons - Dr. Satish Midha Dr. Atul Sharma</p> <p>Panel Discussion: Practice Changing Papers in Esophageal / Gastric Cancers</p> <p>Moderator: Dr. Vedant Kabra</p> <p>Panelists: Dr. Rajesh Shinde Dr. Rudraprasad Acharya Dr. Gajanan Kanitkar Dr. Sandeep De Dr. Indranil Mallick Dr. Nikhil Kalyani Dr. Nilesh Lokeshwar Dr. Nikhil Gulavani Dr. Mukurdipi Ray</p>

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute**
Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 2 | 23rd July 2022 **Scientific Program**

Session 2 : Pancreatic Cancer

7:10pm – 7:35pm

Chairpersons -
Dr. D. C. Doval
Dr. Abhijit Talukdar

**Debate : Borderline Resectable
Pancreatic Cancer**

To Radiate : Dr. Manish Chandra

Not To Radiate: Dr. Shaikat Gupta

Debate Moderator:
Dr. Adarsh Chaudhary

7:35 – 7:50pm

**Advances in the Systemic Treatment
of Pancreatic Cancer**

Speaker: Dr. Niti Raizada

7:50pm – 8:20pm

Chairpersons -
Dr. Sanjay Sonar
Dr. Shefali Agrawal

**Panel Discussion: Practice Changing
Papers in Pancreatic Cancers**

Moderator: Dr. Chetan Kantharia

Panelists:
Dr. Rajat Bhargava
Dr. Caleb Harris
Dr. Ramakrishnan A.S.
Dr. Deepanjali Adulkar
Dr. Upasna Saxena
Dr. Amol Dongre
Dr. Krishnakumar Rathnam
Dr. Sujai Hegde



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 2 | 23rd July 2022 Scientific Program

Session 3 : Hepatocellular Carcinoma / Ca Gall Bladder

8:20pm – 8:45pm

Chairpersons -
Dr. S. H. Advani
Dr. Naresh Somani

**Debate : Integrating Immunotherapy
Into Earlier-Stage HCC**

Yes – Dr. Pritam Kataria

Not Yet – Dr. Ravi Jaiswal

Debate Moderator:
Dr. Adwaita Gore

8:45pm – 9:00pm

**Leaping the Boundaries of Liver
Cancer Surgery**

Speaker: Dr. Ganesh Nagrajan

9:00pm – 9:30pm

Chairpersons -
Dr. Vivek Agarwala
Dr. Shishir Shetty

**Panel Discussion: Practice Changing
Papers in HCC/Gall Bladder**

Moderator: Dr. Vineet Talwar

Panelists:
Dr. Shraddha Patkar
Dr. Aniruddha Kulkarni
Dr. Nikhil Pande
Dr. Chandrakanth M.V.
Dr. Suhas Aagre
Dr. Sandeep Bhoirwal
Dr. Shailesh Bondarde
Dr. Chandrashekhar Pethe



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 3 | 24th July 2022 **Scientific Program**

Session 4 : Colorectal Cancers

6:00pm – 6:10pm	<p>Chairpersons - Dr. K. Pavithran Dr. Mehul Bhansali</p> <p>Tailoring Treatment for Early-Stage CRC</p> <p>Speaker: Dr. Avanish Saklani</p>
6:10pm – 6:35pm	<p>Debate: What's the Best Sequence of Therapy for Locally Advanced Rectal Cancer?</p> <p>Radiation First : Dr. Reena Engineer Chemotherapy First : Dr. Chetan Deshmukh</p>
6:35pm – 6:45pm	<p>Finding the Optimal Window for Anti-EGFR Treatment</p> <p>Speaker: Dr. Prasad Narayanan</p>
6:45pm – 6:55pm	<p>New and Emerging Later-Line Therapies in Advanced CRC</p> <p>Speaker: Dr. Rahul Kulkarni</p>
6:55pm – 7:20pm	<p>Chairpersons - Dr. Rajeev Joshi Dr. Avinash Supe</p> <p>Debate: Quadruple or Triple Therapy in First-Line Advanced CRC</p> <p>Quadruple Therapy : Dr. Bhuvan Chugh Triplet Therapy Dr. Prabhat Bhargava</p> <p>Moderator: Dr. Manish Kumar</p>



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 3 | 24th July 2022 **Scientific Program**

Session 4 : Colorectal Cancers

7:20pm – 7:50pm

Panel discussion: Practice Changing Abstracts in CRC

Moderator: Dr. Nitesh Rohatgi

Panelists:

Dr. Wesley Jose

Dr. Nirmal Raut

Dr. Smita Kayal

Dr. Ashwin Desouza

Dr. Deep Goel

Dr. Sandeep Nayak

Dr. Poornima Subrahmanya

7:50pm – 8:50pm

Chairpersons -

Dr. Anuradha Chougule

Dr. P. K. Julka

Molecular Tumour Board

Moderator: Dr. T. Raja

Panelists:

Dr. Amit Rauthan

Dr. B. K. Smruti

Dr. Suparna Rao

Dr. Tejinder Singh

Dr. Uma Dangi

Dr. Bharat Bhosale

8:50pm – 9:00pm

Vote of Thanks

Conference managed by:

riverroute[®]

▣ Leaders in Streaming Modules

Amey Kadam

Conference Secretariat

rrcg.amey@gmail.com | Mobile +91 98212 41572

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute[®]**
▣ Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Supported By

Diamond Sponsor



Platinum Sponsor



Gold Sponsors



Silver Sponsors



S-One Trio

15 mg
20 mg

Tegafur + Gimeracil + Oteracil Potassium

for

Advanced Gastric Cancer together with Cisplatin



Tegafur

Prodrug of
5-fluorouracil (5-FU)
Replacement for infusional 5-
FU therapy

**Increased
Convenience**

Oteracil

Modulator to reduce
unwanted
5-FU-induced
gastrointestinal toxicity,
as it is related to
phosphorylation of 5-FU

**Reduced
Toxicity**

Gimeracil

Modulator to enhance the
efficacy of tegafur by
inhibiting catabolism and
subsequent inactivation of 5-
FU by inhibiting the enzyme
DPD, so that concentrations
of 5-FU are maintained for a
longer period of time

**Enhanced
Efficacy**



Durable, long-term survival now possible across tumours*



1L aRCC

OPDYTA®, in combination with YERVOI®, is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced RCC.

NEW 1L mNSCLC



OPDYTA®, in combination with YERVOI®, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDYTA®, in combination with YERVOI® & 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

Dual I-O therapy now approved & available in India

Abridged Prescribing Information (API)

To be sold by retail on the prescription of a Registered Oncologist only YERVOI® 5 mg/mL concentrate for solution for infusion. **Composition:** One vial of 10 mL contains 50mg of Ipilimumab. **Therapeutic Indications:** **Renal Cell Carcinoma (RCC)** Ipilimumab is indicated for treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with nivolumab. **Non-Small Cell Lung Cancer (NSCLC)** Ipilimumab, in combination with nivolumab, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by a validated test, with no EGFR or ALK genomic tumor aberrations. Ipilimumab, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic NSCLC, with no EGFR or ALK genomic tumor aberrations. **Dosage and administration:** **RCC Combination phase:** The recommended dose during the combination phase is ipilimumab 1 mg/kg administered intravenously over a period of 30 minutes every 3 weeks for the first 4 doses in combination with nivolumab 3 mg/kg administered intravenously over a period of 30 minutes, followed by the single-agent phase. Single-agent phase: The recommended dose of nivolumab during the single-agent phase is 3 mg/kg every 2 weeks administered intravenously over a period of 30 minutes. When administered in combination with nivolumab, nivolumab should be given first followed by ipilimumab on the same day. **NSCLC** The recommended dose of ipilimumab in combination with nivolumab is nivolumab 3 mg/kg administered as an intravenous infusion over 30 minutes every 2 weeks and ipilimumab 1 mg/kg administered as an intravenous infusion over 30 minutes every 6 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. The recommended dose of ipilimumab in combination with nivolumab and platinum-doublet chemotherapy is nivolumab 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks and ipilimumab 1 mg/kg administered as an intravenous infusion over 30 minutes every 6 weeks and histology-based platinum-doublet chemotherapy every 3 weeks for 2 cycles until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. **Contraindications:** None. **Warnings and Precautions:** **Immune-related pneumonitis:** For Grade 3 or 4 pneumonitis, ipilimumab in combination with nivolumab must be permanently discontinued. For Grade 2 (symptomatic) pneumonitis, ipilimumab in combination with nivolumab should be withheld. **Immune-related colitis:** For Grade 3 & 4 diarrhea or colitis, ipilimumab in combination with nivolumab must be permanently discontinued. For Grade 2 diarrhea or colitis, ipilimumab in combination with nivolumab should be withheld. **Immune-related hepatitis:** Monitor for change in liver function. For Grade 3 or 4 transaminase or total bilirubin elevation, ipilimumab in combination with nivolumab must be permanently discontinued. For Grade 2 transaminase or total bilirubin elevation, ipilimumab in combination with nivolumab should be withheld. **Immune-related nephritis and renal dysfunction:** Monitor for changes in renal function. For Grade 4 serum creatinine elevation, ipilimumab in combination with nivolumab must be permanently discontinued. For Grade 2 or 3 serum creatinine elevation, ipilimumab in combination with nivolumab should be withheld. **Immune-related endocrinopathies:** Monitor for changes in thyroid function. For symptomatic hypothyroidism, ipilimumab in combination with nivolumab should be withheld, and thyroid hormone replacement should be initiated as needed. For symptomatic hyperthyroidism, ipilimumab in combination with nivolumab should be withheld. Ipilimumab in combination with nivolumab must be permanently discontinued for life-threatening (Grade 4) hyperthyroidism or hypothyroidism. For symptomatic Grade 2 adrenal insufficiency, ipilimumab in combination with nivolumab should be withheld. Ipilimumab in combination with nivolumab must be permanently discontinued for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. For symptomatic Grade 2 or 3 hypophysitis, ipilimumab in combination with nivolumab should be withheld. Ipilimumab in combination with nivolumab must be permanently discontinued for life-threatening (Grade 4) hypophysitis. For symptomatic diabetes, ipilimumab in combination with nivolumab should be withheld. Ipilimumab in combination with nivolumab must be permanently discontinued for life-threatening (Grade 4) diabetes. **Immune-related skin adverse reactions:** Ipilimumab in combination with nivolumab should be withheld for Grade 3 rash and discontinued for Grade 4 rash. If symptoms or signs of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) appear, ipilimumab in combination with nivolumab should be withheld. If the patient has confirmed SJS or TEN, permanent discontinuation of ipilimumab in combination with nivolumab is recommended. **Other immune-related adverse reactions:** Ipilimumab in combination with nivolumab should be withheld for grade 3 (first occurrence) & should be permanently discontinued for Grade 4 or recurrent Grade 3 adverse reactions, Persistent Grade 2 or 3 adverse reactions despite management, inability to reduce corticosteroid dose to 10 mg prednisone or equivalent per day. For grade 3 myocarditis, nivolumab or nivolumab in combination with ipilimumab therapy should be permanently discontinued. Fatal or serious graft versus-host disease (GVHD) can occur in patients who receive a CTLA-4 receptor blocking antibody either before or after allogeneic hematopoietic stem cell transplantation (HSCT). Follow patients closely for evidence of GVHD and intervene promptly. **Infusion reaction:** In case of a severe or life-threatening infusion reaction, ipilimumab in combination with nivolumab infusion must be discontinued. Patients with mild or moderate infusion reaction may receive ipilimumab in combination with nivolumab with close monitoring and use of premedication according to local treatment guidelines for prophylaxis of infusion reactions. **Drug Interactions:** Ipilimumab is a human monoclonal antibody that is not metabolized by cytochrome P450 enzymes (CYPs) or other drug metabolizing enzymes. Other forms of interaction **Corticosteroids** The use of systemic corticosteroids at baseline, before starting ipilimumab, should be avoided. However, systemic corticosteroids or other immunosuppressant can be used after starting ipilimumab to treat immune-related adverse reactions. **Anticoagulants** The use of anticoagulants is known to increase the risk of gastrointestinal hemorrhage. Since gastrointestinal hemorrhage is an adverse reaction with ipilimumab, patients who require concomitant anticoagulant therapy should be monitored closely. **Pregnancy:** Ipilimumab is not recommended during pregnancy or in women of childbearing potential not using effective contraception, unless the clinical benefit outweighs the potential risk. **Nursing Mothers:** Discontinue breastfeeding. **Pediatric Use:** The safety and efficacy have not been established. **Geriatric Use:** No overall differences in safety or efficacy were reported between elderly (≥65 years) and younger patients (<65 years). **Hepatic Impairment:** Administer with caution in patients with transaminase levels 5 times ULN or greater, or bilirubin levels greater than 3 times ULN at baseline. **Renal Impairment:** No specific dose adjustment is necessary in patients with mild to moderate renal impairment. **Adverse Reactions:** Fatigue, rash, pruritus, diarrhea, nausea, hypothyroidism, musculoskeletal pain, arthralgia, decreased appetite, pyrexia, vomiting and hyperthyroidism. Ipilimumab is associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of ipilimumab. **Overdose:** Closely monitor for signs and symptoms of adverse reactions and appropriate symptomatic treatment should be instituted. **Storage:** Store in a refrigerator (2°C-8°C). Do not freeze. API based on prescribing information version 03.1, dated 11 May 2021 Issued - 02 July 2021 Before prescribing, consult full prescribing information. For further information, please contact: Bristol-Myers Squibb India Private Limited, 6th floor, Tower 1, One International Center, S.B. Marg, Elphinstone (W), Mumbai - 400 013, Tel: + 91 22 6628 8600.

*Claim applies to CM 227 & CM 214


aRCC: Advanced renal cell carcinoma, 1L: First-line, NSCLC: Non-small cell lung cancer | EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase | Reference: 1. YERVOI® Prescribing Information (PI) dated 11 May 2021 (versions 3.1)



NOW
APPROVED IN



OPDYTA® is the only IO approved in 13 indications in India



NSCLC: Non-small Cell Lung Cancer; RCC: Renal Cell Carcinoma; SCCHN: Squamous Cell Carcinoma of the Head and Neck; mMel.: metastatic Melanoma; Adj. Mel.: Adjuvant Melanoma; CRC: Colorectal Cancer; UC: Urothelial Carcinoma; cHL: Classical Hodgkin Lymphoma; ESCC: Esophageal Squamous Cell Carcinoma; Adj. EC/GEJC: Adjuvant treatment of resected Esophageal Cancer or Gastroesophageal Junction Cancer; GC: Gastric Cancer; GEJC: Gastroesophageal Junction Cancer; EAC: Esophageal Adenocarcinoma; FOLFOX: Folinic acid, fluorouracil, and oxaliplatin; CapeOX: Capecitabine plus oxaliplatin

IO: Immuno-Oncology
*Please refer to complete indication wording mentioned below in API.
OPDYTA® (Nivolumab) India Prescribing Information version 11 dated 11 Aug 2021.
Kindly refer to the full prescribing information before.

Abridged Prescribing Information

To be sold by retail on the prescription of a Registered Oncologist only.

OPDYTA® 10 mg/mL concentrate for solution for infusion. Composition: One vial of 4 mL contains 40 mg of nivolumab; One vial of 10 mL contains 100 mg of nivolumab. **Therapeutic Indications:** Non-Small Cell Lung Cancer (NSCLC): As a single agent for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy; Nivolumab, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by a validated test, with no EGFR or ALK genomic tumor aberrations. Nivolumab, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations; Renal Cell Carcinoma (RCC): As a single agent for the treatment of patients with advanced RCC after prior therapy in adults and for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab; Squamous Cell Carcinoma of the Head and Neck (SCCHN): As monotherapy for the treatment of recurrent or metastatic SCCHN after platinum-based therapy; Melanoma: As a single agent for the treatment of patients with BRAF V600 wildtype unresectable or metastatic melanoma, as a single agent for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma, For the treatment of patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting; Classical Hodgkin Lymphoma (cHL): For the treatment of adult patients with cHL that has relapsed or progressed after – autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin / 3 or more lines of systemic therapy that includes autologous HSCT; Hepatocellular Carcinoma (HCC): For the treatment of patients with HCC who have been previously treated with sorafenib; Urothelial Carcinoma (UC): For the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy OR have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy; Colorectal Cancer (CRC): As monotherapy for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Esophageal Squamous Cell Carcinoma (ESCC): for the treatment of patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy; Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma (GC, GEJC or EAC): Nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; Adjuvant treatment of Resected Esophageal or Gastroesophageal Junction Cancer (EC or GEJC): As monotherapy for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). **Dosage and administration: Nivolumab as monotherapy (NSCLC, RCC, SCCHN, melanoma, cHL, HCC, UC, CRC) - 3 mg/kg administered intravenously every 2 weeks over 30 minutes. Nivolumab as monotherapy for ESCC, EC and GEJC:** Weight-based dosing- 3 mg/kg every 2 weeks over a period of 30 minutes Or Flat dosing- 240 mg every 2 weeks or 480 mg every 4 weeks. For adjuvant treatment, the maximum duration of nivolumab is 12 months. **Nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy GC, GEJC and EAC:** 360 mg Nivolumab intravenously over 30 minutes in combination fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg nivolumab intravenously over 30 minutes in combination with fluoropyrimidine and platinum-based chemotherapy every 2 weeks until disease progression or unacceptable toxicity. The maximum treatment duration for nivolumab is 24 months. **Nivolumab in combination with ipilimumab and platinum-based chemotherapy (NSCLC):** The recommended dose is 360 mg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks in combination with 1 mg/kg ipilimumab administered as an intravenous infusion over 30 minutes every 6 weeks, and platinum chemotherapy administered every 3 weeks. After completion of 2 cycles of chemotherapy, treatment is continued with 360 mg nivolumab administered as an intravenous infusion every 3 weeks in combination with 1 mg/kg ipilimumab every 6 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. **Nivolumab in combination with ipilimumab (RCC): Combination phase:** nivolumab 3 mg/kg over 30 minutes every 3 weeks for the first 4 doses in combination with ipilimumab 1 mg/kg over 30 minutes, followed by the single-agent phase. **Single-agent phase:** 3 mg/kg every 2 weeks over 30 minutes. The first dose of nivolumab monotherapy should be administered 3 weeks following the last dose of the combination of nivolumab and ipilimumab. When administered in combination with ipilimumab, nivolumab should be given first followed by ipilimumab on the same day. **Safety related information. Contraindications:** None. **Warnings and Precautions: Recommended treatment modifications for nivolumab or nivolumab in combination with ipilimumab** **Immune-related pneumonitis:** Withhold for grade 2 and permanently discontinue for grade 3 or 4 pneumonitis. **Immune-related colitis:** Withhold for Grade 2 diarrhoea or colitis. Withhold Nivolumab monotherapy for Grade 3 diarrhoea or colitis. Permanently discontinue nivolumab + ipilimumab for Grade 3 & 4 diarrhoea or colitis. Permanently discontinue nivolumab monotherapy for Grade 4 diarrhoea or colitis. **Immune-related hepatitis:** Monitor for change in liver function. Withhold for grade 2 and permanently discontinue for grade 3 or 4 elevation in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin. **Immune-related nephritis and renal dysfunction:** Monitor for changes in renal function. Withhold for grade 2 or 3 and permanently discontinue for grade 4 serum creatinine elevation. **Immune-related endocrinopathies:** Monitor for changes in thyroid function. Initiate thyroid hormone replacement as needed. Monitor for hyperglycemia. Withhold for symptomatic grade 2 or 3 and permanently discontinue for grade 4 hypophysisitis. Withhold for grade 2 and permanently discontinue for grade 3 or 4 adrenal insufficiency. Withhold for symptomatic grade 2 or 3 and permanently discontinue for grade 4 hypothyroidism or hyperthyroidism. Withhold for grade 3 and permanently discontinue for grade 4 diabetes. **Immune-related skin adverse reactions:** Withhold for grade 3 rash or suspected Stevens- Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and permanently discontinue for grade 4 rash or confirmed SJS/TEN. **Other immune-related adverse reactions:** Withhold for grade 3 (first occurrence) and permanently discontinue for grade 3 myocarditis, grade 4 or recurrent grade 3, persistent grade 2 or 3 despite treatment modification, inability to reduce corticosteroid dose to 10 mg prednisone or equivalent per day. When nivolumab is administered in combination with ipilimumab, if either agent is withheld, the other agent should also be withheld. If dosing is resumed after a delay, either the combination treatment or nivolumab monotherapy could be resumed based on the evaluation of the individual patient. **Complications of allogeneic hematopoietic stem cell transplant (HSCT) after Nivolumab:** Monitor for transplant-related complications, including CVHD. Fatal cases have been reported in clinical studies. **Infusion reaction:** Discontinue for severe and life-threatening infusion reactions. Patients with mild or moderate infusion reaction may receive nivolumab or nivolumab in combination with ipilimumab with close monitoring and use of premedication according to local treatment guidelines. **Increased mortality in patients with multiple myeloma (not an approved indication) when a PD-1 blocking antibody is added to a thalidomide analogue and dexamethasone:** Treatment of patients with multiple myeloma with a PD-1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. **Drug Interactions:** Inhibition or induction of cytochrome P450 (CYP) enzymes or other drug metabolizing enzymes by coadministered medicinal products is not anticipated to affect the pharmacokinetics of nivolumab. The use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided. However, these can be used after starting nivolumab to treat immune-related adverse reactions. **Pregnancy:** Not recommended during pregnancy and in women of childbearing potential not using effective contraception unless the clinical benefit outweighs the potential risk. Women should be advised to use effective contraception for at least 5 months following the last dose of nivolumab. **Nursing Mothers:** Discontinue breastfeeding. **Pediatric Use:** The safety and efficacy have not been established. **Geriatric Use:** No dose adjustment is required for elderly patients (≥65 years) **Hepatic Impairment:** No dose adjustment is required in patients with mild or moderate hepatic impairment. **Renal Impairment:** No specific dose adjustment is necessary in patients with mild to moderate renal impairment. **Adverse Reactions:** Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, vomiting, neutropenia, hypothyroidism. Nivolumab is associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of Nivolumab. **Overdose:** Closely monitor for signs and symptoms of adverse reactions and institute appropriate symptomatic treatment. **Storage:** Store in a refrigerator (2°C-8°C). Do not freeze. API based on prescribing information version 11 dated 11 Aug 2021. Issued – 11 Jan 2022.

FORTITUDE WITH **5** YEARS* INDICATIONS



2nd Line advanced Gastric
Cancer / GE Junction
adenocarcinoma



1st Line EGFRm+
metastatic Non Small
Cell Lung Cancer



2nd Line locally
advanced or metastatic
Non Small Cell Lung Cancer



2nd Line metastatic
Colorectal Cancer



2nd Line advanced
or unresectable
Hepatocellular Carcinoma

22nd - 24th JULY 2022

Don't let HCC put a stopper on his joys.
Let these little joys continue whole-heartedly for him.

IN 1L UNRESECTABLE HCC OR mHCC¹

Study	Year	Population	Exposure	Outcome	OR (95% CI)
1	1984	10,000	100	10	1.0
2	1985	10,000	100	10	1.0
3	1986	10,000	100	10	1.0
4	1987	10,000	100	10	1.0
5	1988	10,000	100	10	1.0
6	1989	10,000	100	10	1.0
7	1990	10,000	100	10	1.0
8	1991	10,000	100	10	1.0
9	1992	10,000	100	10	1.0
10	1993	10,000	100	10	1.0
11	1994	10,000	100	10	1.0
12	1995	10,000	100	10	1.0
13	1996	10,000	100	10	1.0
14	1997	10,000	100	10	1.0
15	1998	10,000	100	10	1.0
16	1999	10,000	100	10	1.0
17	2000	10,000	100	10	1.0
18	2001	10,000	100	10	1.0
19	2002	10,000	100	10	1.0
20	2003	10,000	100	10	1.0
21	2004	10,000	100	10	1.0
22	2005	10,000	100	10	1.0
23	2006	10,000	100	10	1.0
24	2007	10,000	100	10	1.0
25	2008	10,000	100	10	1.0
26	2009	10,000	100	10	1.0
27	2010	10,000	100	10	1.0
28	2011	10,000	100	10	1.0
29	2012	10,000	100	10	1.0
30	2013	10,000	100	10	1.0
31	2014	10,000	100	10	1.0
32	2015	10,000	100	10	1.0
33	2016	10,000	100	10	1.0
34	2017	10,000	100	10	1.0
35	2018	10,000	100	10	1.0
36	2019	10,000	100	10	1.0
37	2020	10,000	100	10	1.0
38	2021	10,000	100	10	1.0
39	2022	10,000	100	10	1.0
40	2023	10,000	100	10	1.0
41	2024	10,000	100	10	1.0
42	2025	10,000	100	10	1.0
43	2026	10,000	100	10	1.0
44	2027	10,000	100	10	1.0
45	2028	10,000	100	10	1.0
46	2029	10,000	100	10	1.0
47	2030	10,000	100	10	1.0
48	2031	10,000	100	10	1.0
49	2032	10,000	100	10	1.0
50	2033	10,000	100	10	1.0
51	2034	10,000	100	10	1.0
52	2035	10,000	100	10	1.0
53	2036	10,000	100	10	1.0
54	2037	10,000	100	10	1.0
55	2038	10,000	100	10	1.0
56	2039	10,000	100	10	1.0
57	2040	10,000	100	10	1.0
58	2041	10,000	100	10	1.0
59	2042	10,000	100	10	1.0
60	2043	10,000	100	10	1.0
61	2044	10,000	100	10	1.0
62	2045	10,000	100	10	1.0
63	2046	10,000	100	10	1.0
64	2047	10,000	100	10	1.0

1. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382:1894-1905.

Product name: Bevacizumab Injection Brand name: Avastin[®] Indications: Avastin is indicated for the treatment of Colorectal Cancer (2) Unresected Stage 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832

Marketed in India by :
Roche Products (India) Pvt. Ltd.
 146-B, 166A, Unit No. 7,8,9, 8th Floor,
 R City Office, R City Mall, Lal Bahadur Shastri Marg,
 Ghatkopar, Mumbai - 400 086, India
 Tel: +91 (22) 5045 7300 • Fax : +91 (22) 5045 7301



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022



One dose
Dual action
5-day prevention¹⁻⁵

Akynzeo[®]
netupitant/palonosetron
PREVENTION MADE SIMPLE

Ref. 1. Aggio M et al. Am Oncol. 2014; 25(7):1228-33. 2. Heseth PJ et al. Am Oncol. 2014; 25(7):1340-6. 3. Grillo RJ et al. Am Oncol. 2014; 25(7):1333-6. 4. Rojas C et al. Eur J Pharmacol. 2014; 722:26-37. 5. AKYNZEOR (netupitant/palonosetron HCl) capsules, Summary of Product Characteristics.

AKYNZEOR 300 mg/15 mg hard capsules
ACTIVE INGREDIENTS: 300 mg of netupitant and 15 mg of palonosetron hydrochloride equivalent to 15 mg of palonosetron. **INDICATIONS:** Akynzeo[®] is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy. **POSLOGY AND METHOD OF ADMINISTRATION:** One hard capsule should be administered approximately one hour prior to the start of each chemotherapy cycle. The hard capsule should be swallowed whole and can be taken with or without food. The recommended oral desmethylsine dose should be reduced by approximately 50%. No dosage adjustment is necessary for elderly patients. Caution should be exercised when using in patients over 75 years. The safety and efficacy in the paediatric population have not been established. Dosage adjustment is not considered necessary in patients with mild to severe renal impairment. Use in end-stage renal patients requiring hemodialysis should be avoided. No dosage adjustment is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score 5-6). Caution should be used with patients with severe hepatic impairment (Child-Pugh score ≥ 7). **CONTRAINDICATIONS:** Hypersensitivity to the active substances or to any of the excipients. Pregnancy. **WARNING AND PRECAUTIONS:** History of constipation or signs of subacute ileus obstruction. Serotonin syndrome either alone or in combination with selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs). The use of medicinal products that increase the QT interval or the use in patients who have or are likely to develop prolongation of the QT interval. Systemic exposure to other medicines metabolized by CYP3A4. Breastfeeding should be discontinued during treatment with Akynzeo[®]. Patients with new-onset problems of fatigue, intolerance, diarrhoea, malabsorption or gastrointestinal insufficiency should not take Akynzeo[®]. Patients with known hypersensitivity to peanut or soya should be monitored closely for signs of an allergic reaction. **INTERACTIONS:** concomitant use of drugs that induce CYP3A4 activity can decrease efficacy of Akynzeo[®]. Akynzeo[®] can increase plasma concentrations of drugs that are metabolized via CYP3A4. The inhibitory effect on CYP3A4 can last for multiple days. Desmethylsine doses should be reduced when given with Akynzeo[®]. Exposure to doxorubicin and epirubicin was increased when coadministered with Akynzeo[®]. No consistent effect was seen with hydrophobic drugs after repeated co-administration. The potential effects of increased plasma concentrations of antineoplastic, anticancer or other leucodermatogenic metabolized via CYP3A4 (irinotecan, irinotecan) when administered with Akynzeo[®] should be considered. Concomitant use of Akynzeo[®] in patients on chronic use of a strong CYP3A4 inducer such as dexamethasone should be avoided as this may decrease the efficacy of Akynzeo[®]. Concomitant administration with strong CYP3A4 inhibitors such as voriconazole should be approached with caution. Caution is recommended when netupitant is combined with an oral substrate of UGT2B7 (e.g. zolpidem, valproic acid, morphine) as in vitro data shows that netupitant inhibits this enzyme. Caution is recommended when netupitant is combined with digoxin or with other P-gp substrates such as dabigatran, or citalopram, or citalopram as in vitro data show that netupitant inhibits this enzyme. **FERTILITY, PREGNANCY AND LACTATION:** Women of childbearing potential should not be pregnant or become pregnant while on treatment with Akynzeo[®] and a pregnancy test should be performed on all premenopausal women prior to treatment. Women of childbearing potential must use effective contraception during therapy and up to one month after treatment with Akynzeo[®]. Akynzeo[®] should not be used during breast-feeding. It should be discontinued during treatment and for 1 month after the last dose with AKYNZEOR. **ADVERSE REACTIONS:** Common: Headache, Constipation, Fatigue, Urinary tract infection, Nausea, Leucopenia, Decreased appetite, Insomnia, Dizziness, Vertigo, Abnormal heart block first degree, Cardiac arrhythmia, Conduction disorder, Hypertension, Hypocapnia, Abdominal pain, Diarrhoea, Dyspepsia, Flatulence, Nausea, Alopecia, Urinary tract infection, Liver transaminases increased, Blood creatinine increased, Electrocardiogram QT prolonged, Rare: Otitis, Leucopenia, Lymphopenia, Hypokalaemia, Acute psychosis, Mood altered, Sleep disorder, Hypoaesthesia, Conjunctivitis, Vision blurred, Arrhythmia, Abnormal heart block second degree, Bundle branch block, Mild valve incompetence, Myocardial infarction, Ventricular extrasystoles, Hypotension, Dysphagia, Tongue coated, Back pain, Feeling hot, Non-cardiac chest pain, Prostate test abnormal, Blood bilirubin increased, Blood creatine phosphokinase MB increased, Electrocardiogram ST segment depression, Electrocardiogram ST-T segment abnormal, Tropicamide increased, Very rare: anaphylaxis, anaphylactoid reactions and shock have been reported from the post-marketing use of intravenous palonosetron. Overdose: No specific information is available on the treatment of overdose with Akynzeo[®]. In case of overdose Akynzeo[®] should be discontinued and general supportive treatment and monitoring should be provided.

Legal category: Medical Prescription Product. Marketing authorisation number: EU/1/15/101/001. Marketing authorisation holder: Helsinn Biotech Pharmaceuticals Ltd, Darnestown, Mulhuddart, Dublin 15, Ireland. Reporting suspected adverse reactions after authorisation of Akynzeo[®] is important. It allows continued monitoring of the benefit/risk balance of Akynzeo[®]. Healthcare professionals are asked to report any suspected adverse reactions according to their national provisions. Adverse reactions should also be reported to Helsinn Biotech Pharmaceuticals Ltd, (address as above) Tel: +353 86 8365321. Akynzeo[®] is a registered trademark of Helsinn Healthcare SA, Switzerland. Akynzeo[®] is marketed in India exclusively by Glenmark Pharmaceuticals.

ASPI PhC, Akynzeo[®] June 2020
For further product related queries contact: Glenmark Pharmaceuticals Limited (GPI), Corporate Enclave, B. D. Sawant Marg, Chhatrapati, Andheri (E), Mumbai – 40, Email id: global.customerservice@glenmarkpharma.com
For any adverse event related to Glenmark marketed product contact on: global.customerservice@glenmarkpharma.com



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

For the management of advanced HCC

^{Rx} **Lenvenib**[®]
Lenvatinib 4mg/10mg Capsules
a **NEW** standard

^{Rx} **Cabozat**[™]
Cabozantinib 20/40 mg Tablets
*Improve **Survival** with a **Masterstroke***

- Developed **in house** right from basic API to finished product*
- **Bioequivalent** to the innovator
- Manufactured in **USFDA** approved plant for benchmark quality*



* Data on file.



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

With Best Compliments from



Makers of

Fulzos
FULVESTRANT 250 mg PFS

RE-SETLife



CIZUMABTM
BEVACIZUMAB 100 mg / 400 mg Inj.

Impeding **Angiogenesis**



A / B - 201 / 202, Dipti Classic, 32 / 34, W.T. Suren Road, Andheri (East), Mumbai - 400 093, India
Tel: +91 22 2684 93 38 / 39 / 40 Fax: +91 22 2684 9355 E-mail: ho@heterohealthcare.com



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022



A stapling solution
that **optimizes perfusion and
reduces leaks at the staple line**¹

ECHELON CIRCULAR™ Powered Stapler



ETHICON
PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

Shaping
the future
of surgery

¹ Rajakumar P, Henderson CE, Hill S, Jenkins SA, Paulin-Gurley GG, et al. (2017).
A novel powered circular stapler designed for creating secure anastomoses.
Med Devices Diagn Eng. 2. DOI: 10.15761/MDDOE1000123



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Dr.Reddy's 
Oncology



Dacotin

Oxaliplatin Inj. 50, 100 mg

The Original Oxaliplatin



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Dr.Reddy's 
Oncology

Sideline Cutaneous Toxicities With A Non-Steroidal Gel

ADVANCED FORMULATION

Strata

A GEL TO FIGHT WELL

ctx[®]